Streetwise Expert Interviews

Michael Higgins

How to Beat the Herd Mentality: Highline's Michael Higgins

Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't propel a stock against powerful global or industry-wide headwinds. In this interview with The Life Sciences Report, Higgins, an industry veteran, discusses his methods of finding winning plays in the biotech space, and selects three names that could spike the punch in your portfolio.

(2/25/15) More >
Read More Streetwise Interviews

Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn

Immuno-oncology—disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it—took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015. (2/19/15) More >

Newsletter Briefs

"Investors should keep a close eye on CBMG during 2015." (2/19/15) Cellular Biomedicine Group Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

"There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >

"RNN's RX-3117 showed the ability to stop tumor growth from 62–100%." (1/13/15) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein More >

Expert Analysis

"In Q1/15, CANF anticipates completion of the A3AR biomarker." (2/24/15) Can-Fite BioPharma Ltd. - Sharon di Stefano, Seeking Alpha More >

"We are raising our price target for OMER." (2/20/15) Omeros Corp. - Jason Kolbert, Maxim Group More >

"Malaysia was cleared for enrollment in CVM's Phase 3 clinical trial." (2/20/15) CEL-SCI Corporation - Robert Wasserman, Dawson James Securities More >

"We believe that MSB's MSC-100IV will be approved in children and ultimately adults, and that it will save lives." (2/18/15) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"We are raising our price target for OMER." (2/18/15) Omeros Corp. - George Zavoico, MLV & Co More >

"MSB's new patent covers its MPCs in degenerated disc treatment." (2/10/15) Mesoblast Ltd. - Henry McCusker, Regenerative Medicine Investors More >

"Results from CUR's Phase 2 ALS trial will be announced in Q1/15." (2/10/15) Neuralstem Inc. - Larry Smith, SmithOnStocks More >

"OMER looks well positioned for a solid gain but has been overlooked." (2/10/15) Omeros Corp. - Zacks Equity Research More >